pandem
stun
world
financi
market
healthcar
system
research
rush
identifi
effect
treatment
maintain
rigor
adher
scientif
method
clinician
best
provid
evidencebas
care
set
littl
good
evid
date
effect
treatment
exist
manag
unfortun
tradit
social
media
coupl
world
leader
commentari
led
believ
hydroxychloroquin
offer
bona
fide
cure
even
prevent
purpos
commentari
review
medic
literatur
relat
hydroxychloroquin
build
knowledg
past
year
sinc
sarscov
epidem
hydroxychloroquin
use
treatment
malaria
sinc
approv
treatment
rheumatoid
arthriti
lupu
current
potenti
mechan
action
hydroxychloroquin
effect
fulli
known
hypothes
increas
endosom
ph
may
inhibit
viral
fusion
replic
interfer
receptor
glycosyl
receptor
chloroquin
hydroxychloroquin
seem
effect
kill
sarscov
vitro
recent
report
show
also
may
effect
kill
cell
vitro
unfortun
effect
treatment
vitro
frequent
translat
vivo
efficaci
hydroxychloroquin
yet
determin
preclin
anim
vivo
model
accur
model
human
safeti
efficaci
enabl
better
predict
translat
failur
human
chloroquin
found
efficaci
mous
model
infect
sarscov
despit
multipl
dose
schedul
treatment
rout
date
preclin
studi
evalu
efficaci
hydroxychloroquin
current
pandem
recent
articl
publish
chines
found
benefit
chloroquin
random
trial
patient
yet
publish
random
control
trial
hydroxycholoroquin
recent
public
gautret
et
al
tout
nonmed
public
figur
proof
cure
led
signific
interest
news
outlet
social
media
gener
public
studi
nonrandom
nonblind
open
label
underpow
trial
given
limit
meet
rigor
evalu
scientif
efficaci
illustr
gautret
et
al
treat
patient
hydroxychloroquin
six
receiv
concomit
azithromycin
met
studi
inclus
criteria
control
group
subsequ
made
patient
meet
studi
inclus
criteria
primari
outcom
viral
load
defin
cycl
time
ct
threshold
ct
number
revers
transcript
pcr
cycl
necessari
detect
presenc
viral
rna
lower
ct
associ
increas
viral
load
ct
greater
equal
deem
neg
viral
titer
unclear
whether
threshold
set
priori
post
hoc
enrol
patient
interim
analysi
conduct
publish
critic
result
exclus
six
patient
treatment
arm
one
die
three
decompens
requir
transfer
icu
one
withdrew
studi
due
drugrel
complic
one
lost
followup
patient
exclud
author
final
analysi
author
compar
viral
titer
patient
receiv
hydroxychloroquin
combin
azithromycin
control
patient
inelig
receiv
hydroxychloroquin
unadjust
analys
author
identifi
significantli
reduc
viral
titer
hydroxychloroquin
arm
comment
made
regard
higher
mortal
complic
advers
event
rate
hydroxychloroquin
group
exclud
poorli
hydroxychloroquin
bias
analysi
impact
potenti
valid
studi
reincorpor
patient
statist
analysi
would
significantli
chang
result
studi
hydroxychloroquin
group
patient
suffer
death
medic
deterior
advers
event
compar
control
arm
barnard
test
p
number
need
harm
nnh
data
random
control
trial
avail
suggest
caution
util
hydroxychloroquin
label
patient
report
overdos
occur
current
evid
support
hydroxychloroquin
prophylaxi
unfortun
data
extrapol
indic
potenti
result
drug
shortag
patient
rheumat
diseas
requir
medic
furthermor
caution
medic
world
leader
prematur
comment
treatment
efficaci
pandem
comment
may
exacerb
shortag
patient
reliant
medic
caus
harm
due
medic
side
effect
overdos
